Diabetic Dyslipidemia Management
- Diabetic dyslipidemia is characterized by hypertriglyceridemia, high levels of apoB, non-HDL-C and small-dense LDL particles.
- Moderate- to high-intensity statins remain the cornerstone for treatment of diabetic dyslipidemia based on ASCVD risk and other risk enhancers.
- Ezetimibe is now recommended as the first add-on therapy to statins because of the cost consideration. PCSK9 inhibitors are the next class of drugs added to lipid management as they have proven safety and efficacy, with expected future decreases in cost.
- Icospent ethyl holds promise in diabetic dyslipidemia as it reduces TG and improves CV outcomes; add-on to statin if TG 135-499 mg/dL.
- Combination of statins and fibrates is not routinely recommended.
Dr. S K Wangnoo
Dr. S K Wangnoo is a Senior Consultant Endocrinologist at the Apollo Centre for Obesity, Diabetes & Endocrinology (ACODE) of Indraprastha Apollo Hospitals in Sarita Vihar, New Delhi. He is also Honorary Physician Endocrinologist to the President of India. After obtaining the MBBS (1976) and MD Medicine (1981) degrees, Dr. Wangnoo successfully completed the DM (Endocrinology) Examination in 1984.
More FAQs by Dr. S K Wangnoo
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article